|
|
Volumn 4, Issue 2, 2014, Pages 136-
|
|
IPI-145 shows promise in CLL patients
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DUVELISIB;
IDELALISIB;
OFATUMUMAB;
PHOSPHATIDYLINOSITOL 3 KINASE;
PROTEIN P53;
BLOOD TOXICITY;
CANCER CHEMOTHERAPY;
CHRONIC LYMPHATIC LEUKEMIA;
DISEASE COURSE;
DRUG EFFICACY;
DRUG SAFETY;
GENE MUTATION;
HIGH RISK PATIENT;
HUMAN;
LYMPHADENOPATHY;
NEUTROPENIA;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
TREATMENT RESPONSE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I AS TOPIC;
HUMANS;
ISOQUINOLINES;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
PURINES;
TREATMENT OUTCOME;
|
|
EID: 84896732134
PISSN: 21598274
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2013-177 Document Type: Note |
|
Times cited : (13)
|
|
References (0)
|